Key result
Dapagliflozin improves symptoms and lowers NT-proBNP in rare ApoA1 cardiac amyloidosis.
Why the study?
Reports for effective therapy in rare hereditary cardiac amyloidosis are limited.
Case Report (n=1)
SGLT2 inhibitors such as dapagliflozin may provide symptom relief and clinical stability in patients with rare hereditary cardiac amyloidosis (e.g., ApoA1 variants).
Answers are grounded in this paper and cite their sources.
May support SGLT2i exploration in ApoA1 amyloidosis; extends TTR observations but remains hypothesis-generating.
BACKGROUND: Rare hereditary cardiac amyloidosis (CA) may mimic transthyretin or light-chain cardiomyopathy, and reports for effective therapy in these entities are limited. CASE SUMMARY: A 61-year-old man presented with progressive heart failure (NYHA functional class III). Medical history included bilateral carpal tunnel syndrome, chronic kidney disease, and family history notable for amyloidosis in his brother and suspected CA-related death in their mother. Cardiac magnetic resonance imaging showed late gadolinium enhancement consistent with CA, echocardiography increased left ventricular thickness and diastolic dysfunction. Light-chain CA was excluded. Genetic testing identified an Apolipoprotein A-I (ApoA1) mutation (p.L202P). ApoA1 amyloid was confirmed in a gastric biopsy. Therapy with dapagliflozin led to clinical improvement. DISCUSSION: Recognition of ApoA1-associated CA relies on clinical history and genetic confirmation. Screening of first-degree relatives is advised. SGLT2-inhibitor therapy may improve symptoms, extrapolated from observational transthyretin-cardiomyopathy studies. TAKE-HOME MESSAGE: Rare hereditary CA represents an important differential diagnosis in CA cases. Sodium-glucose cotransporter 2 inhibitors may represent a treatment option.
No takes yet. Share an insight, caveat, or question.
Voran et al. (2026) conducted a case report in Rare hereditary cardiac amyloidosis (ApoA1-associated) (n=1). Dapagliflozin was evaluated on Clinical symptom improvement and NT-proBNP levels. Dapagliflozin therapy improved symptoms to functional class I and reduced NT-proBNP levels in a 61-year-old man with rare hereditary ApoA1-associated cardiac amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: